García Romero, NoemíCalvo Aller, EmilianoPalacín Aliana, IrinaAyuso Sacido, ÁngelMadurga, RodrigoCarrión-Navarro, JosefaEsteban Rubio, SusanaJiménez, BeatrizCollazo, A.Pérez-Rodríguez, FelipeFernández-Carballal, C.García-Duque, S.Diamantopoulos-Fernández, J.Belda Iniesta, CristóbalPrat-Acín, R.Sánchez-Gómez, P.Ortiz de Mendivil Arrate, AnaGrupo: Spanish Back Pain Research Network (REIDE)2024-02-082024-02-082020-06-22García-Romero, N., Palacín-Aliana, I., Madurga, R. et al. Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. BMC Med 18, 142 (2020). https://doi.org/10.1186/s12916-020-01610-01741-7015http://hdl.handle.net/10637/15397Background: Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. Methods: We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment. Results: We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance. Conclusions: Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment.application/pdfenopen accessVEGFAAngiogenesisBevacizumabGlioblastomaNeovasculogenesisArtículo10.1186/s12916-020-01610-0https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es